Is Global Health a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Global Health Ltd is a good quality company .

Is Global Health undervalued or overvalued?

The key valuation ratios of Global Health Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Global Health share price return in the past 10 years?

Data is not available for this company

Is Global Health a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Global Health Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Global Health Ltd - Stock Valuation and Financial Performance

Name: Global Health
Brand: Global Health

BSE: 543654 | NSE: MEDANTA | Hospital & Healthcare Services | Mid Cap

Place order

Global Health Share Price

₹1,072.45 -13.95 -1.28%
as on 21-Nov'24 16:59

10 Year X-Ray of Global Health:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	26.5%	26.4%	8.9%	6.8%	8.3%	11.3%	7.7%	19.5%	17.2%	18.9%	-
Value Creation Index ⓘ	1.4	1.4	-0.2	-0.4	-0.3	0	-0.3	0.4	0.3	0.7	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1,194	1,382	1,277	1,343	1,441	1,472	1,227	1,765	1,974	2,280	2,416
Sales YoY Gr.	-	15.7%	-7.6%	5.2%	7.3%	2.2%	-16.6%	43.8%	11.8%	15.5%	-
Adj EPS ⓘ	6.2	7.2	2.3	1.6	2.6	4.1	2.3	8.6	9.9	13.4	14.2
YoY Gr.	-	17.3%	-68.4%	-32.3%	69.7%	57.4%	-44.7%	276.9%	14.5%	35.8%	-
BVPS (₹) ⓘ	35.6	42.5	44.4	46	49.9	54.4	57.2	68.5	92.6	105.9	113.5
Adj Net Profit ⓘ	150	176	55.5	37.5	64.7	102	56.8	219	265	360	380
Cash Flow from Ops. ⓘ	214	228	124	80.1	152	193	201	235	431	341	-
Debt/CF from Ops. ⓘ	0.2	0.6	1.5	2.1	0.9	0.1	0.1	0.5	0.2	0.2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	7.5%	9.6%	22.9%	15.5%
Adj EPS ⓘ	9%	38.5%	80.3%	35.8%
BVPSⓘ	12.9%	16.3%	22.8%	14.4%
Share Price	-	-	-	20%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	18.5	18	5	3.2	5.1	7.5	3.9	13.6	12.5	13.5	12.9
Op. Profit Mgn % ⓘ	22	22.1	10	9.7	10.1	14.9	14.1	21.6	21.5	22.1	21.8
Net Profit Mgn % ⓘ	12.5	12.7	4.3	2.8	4.5	6.9	4.6	12.4	13.4	15.8	15.7
Debt to Equity ⓘ	0.1	0.1	0.2	0.2	0.1	0	0	0.1	0	0	0
Working Cap Days ⓘ	40	42	54	65	73	80	154	158	167	193	92
Cash Conv. Cycle ⓘ	-14	-9	-3	5	9	5	10	9	8	4	61

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 22.93%

Net Profit is growing at healthy rate in last 3 years 80.29%

Sales growth is good in last 4 quarters at 13.37%

Return on Equity has declined versus last 3 years average to 12.90%

Latest Financials - Global Health Ltd.

	Standalone	Consolidated
TTM EPS (₹)	14.2	18.2
TTM Sales (₹ Cr.)	2,416	3,459
BVPS (₹.) ⓘ	113.5	117
Reserves (₹ Cr.) ⓘ	2,995	3,088
P/BV ⓘ	9.57	9.29
PE ⓘ	76.71	59.77

From the Market
52 Week Low / High (₹)	872.05 / 1513.75
All Time Low / High (₹)	391.05 / 1513.75
Market Cap (₹ Cr.)	29,175
Equity (₹ Cr.)	53.7
Face Value (₹)	2
Industry PE ⓘ	40.2

Management X-Ray of Global Health:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Global Health

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Global Health

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	1,194	1,382	1,277	1,343	1,441	1,472	1,227	1,765	1,974	2,280
Operating Expenses ⓘ	931	1,077	1,151	1,213	1,297	1,254	1,054	1,384	1,552	1,777
Manufacturing Costs	50	55	93	139	182	170	206	294	342	382
Material Costs	322	363	285	313	325	314	298	441	459	540
Employee Cost	422	472	519	527	541	522	416	495	533	591
Other Costs ⓘ	138	187	253	234	250	248	135	155	218	263
Operating Profit ⓘ	263	305	127	130	144	219	173	381	422	503
Operating Profit Margin (%)	22.0%	22.1%	9.9%	9.7%	10.0%	14.8%	14.1%	21.6%	21.4%	22.1%
Other Income ⓘ	36	45	67	49	65	44	28	35	48	103
Interest ⓘ	9	14	23	28	21	33	29	33	32	30
Depreciation ⓘ	62	69	81	86	91	99	88	87	86	87
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	229	268	90	64	97	131	84	296	352	489
Tax ⓘ	79	92	35	27	34	28	27	77	88	128
Profit After Tax	150	176	55	37	63	103	57	219	263	361
PAT Margin (%)	12.5%	12.7%	4.3%	2.8%	4.4%	7.0%	4.7%	12.4%	13.3%	15.8%
Adjusted EPS (₹)	6.3	7.3	2.3	1.5	2.6	4.2	2.3	8.6	9.8	13.4
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	881	1,057	1,109	1,148	1,258	1,374	1,451	1,734	2,484	2,844
Share Capital ⓘ	80	81	81	81	82	82	82	51	54	54
Reserves ⓘ	801	976	1,028	1,067	1,177	1,292	1,369	1,684	2,430	2,791
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	40	124	162	148	115	18	19	89	58	0
Long Term Debt	40	113	132	123	115	18	19	89	58	0
Short Term Debt	0	11	30	25	0	0	0	0	0	0
Trade Payables	83	92	104	106	126	118	109	103	142	138
Others Liabilities ⓘ	214	223	288	307	259	497	838	927	1,070	1,244
Total Liabilities ⓘ	1,218	1,496	1,664	1,709	1,758	2,008	2,418	2,854	3,754	4,226
Fixed Assets
Gross Block	980	1,213	1,126	1,167	1,198	1,350	1,354	1,410	1,472	1,581
Accumulated Depreciation	231	300	154	239	329	421	502	583	663	740
Net Fixed Assetsⓘ	749	913	972	928	869	929	851	827	810	841
CWIP ⓘ	23	11	8	7	5	3	4	6	75	184
Investmentsⓘ	9	14	0	0	356	501	626	734	765	790
Inventories	25	28	21	23	23	32	32	40	42	44
Trade Receivables	53	75	107	152	164	148	130	173	173	192
Cash Equivalents	303	371	469	253	240	219	255	441	1,145	959
Others Assetsⓘ	55	84	86	346	101	175	521	632	744	1,216
Total Assets ⓘ	1,218	1,496	1,664	1,709	1,758	2,008	2,418	2,854	3,754	4,226

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	214	228	124	80	152	193	201	235	431	341
PBT ⓘ	229	268	90	64	97	131	84	296	352	489
Adjustment ⓘ	63	76	107	122	105	122	105	100	83	53
Changes in Working Capital ⓘ	-24	-18	-14	-52	3	-4	26	-69	96	-56
Tax Paid ⓘ	-54	-97	-58	-53	-67	-56	-15	-91	-101	-145
Cash Flow From Investing Activity ⓘ	-126	-245	-112	-46	-104	-45	-250	-313	-257	-699
Capex	-76	-156	-90	-49	-29	-17	-23	-64	-115	-185
Net Investments	0	0	-48	-23	36	96	-117	-162	-145	-222
Others ⓘ	-50	-89	26	25	-111	-124	-111	-87	3	-291
Cash Flow From Financing Activityⓘ	-87	-7	-6	-36	-49	-56	-37	98	404	-66
Net Proceeds from Shares ⓘ	1	1	0	0	1	0	0	38	479	0
Net Proceeds from Borrowing ⓘ	0	0	0	-8	-6	-16	0	98	-34	-33
Interest Paid ⓘ	-9	-11	-17	-23	-18	-23	-21	-24	-25	-23
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-79	4	11	-5	-25	-16	-15	-14	-16	-10
Net Cash Flow ⓘ	0	-24	6	-2	-1	92	-86	20	577	-424

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	19.33	18.76	5.24	3.41	5.38	8	4.15	13.88	12.48	13.55
ROCE (%)	26.53	26.39	8.89	6.78	8.29	11.3	7.69	19.51	17.23	18.88
Asset Turnover Ratio	1.02	1.02	0.81	0.8	0.83	0.78	0.55	0.67	0.6	0.57
PAT to CFO Conversion(x)	1.43	1.3	2.25	2.16	2.41	1.87	3.53	1.07	1.64	0.94
Working Capital Days
Receivable Days	14	17	26	35	40	39	41	31	32	29
Inventory Days	7	7	7	6	6	7	10	7	8	7
Payable Days	94	88	126	123	131	142	139	88	98	95

Global Health Ltd Stock News

Global Health Ltd FAQs

What is the share price of Global Health?

Company share prices are keep on changing according to the market conditions. The closing price of Global Health on 21-Nov-2024 16:59 is ₹1,072.5.

What is the market cap of Global Health?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Global Health stood at ₹29,175.

What is the P/E ratio of Global Health?

The latest P/E ratio of Global Health as of 21-Nov-2024 16:59 is 76.71.

What is the P/B ratio of Global Health?

The latest P/B ratio of Global Health as of 21-Nov-2024 16:59 is 9.57.

What is the 52-week high and low of Global Health?

The 52-week high of Global Health is ₹1,513.8 and the 52-week low is ₹872.0.

What is the TTM revenue of Global Health?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Global Health is ₹2,416 ( Cr.) .

About Global Health Ltd

The company was incorporated as ‘Global Health Private Limited’ on August 13, 2004 at New Delhi, India as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation by the Registrar of Companies, Delhi and Haryana at Delhi (RoC). The company was then converted into a public limited company under the Companies Act, 2013, pursuant to a special resolution passed by its Shareholders at the EGM held on July 31, 2021 and consequently, the name of the Company was changed to ‘Global Health Limited’ and a fresh certificate of incorporation dated August 11, 2021 was issued by the RoC.

The company is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India in terms of bed capacity and operating revenues amongst the players that operate in the North and East regions of India, with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology. Under the “Medanta” brand, the company has a network of many hospitals currently in operation (Gurugram, Indore, Ranchi, Lucknow and Patna) and one hospital (Noida), which is under construction. The company strives to deliver advanced healthcare by establishing institutes of excellence that integrate medical care, teaching and research all while providing affordable medical services to patients.

Business area of the company

Global Health is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India. The company has key specialities in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology.

Key awards, accreditations, certifications and recognitions

Accreditations

2011: 1st National Accreditation Board for Hospitals and Healthcare Providers (“NABH”) accreditation for the hospital at Gurugram
2011: 1st National Accreditation Board for Testing and Calibration Laboratories accreditation for the hospital at Gurugram.
2013: 1st Joint Commission International (JCI) accreditation for the hospital at Gurugram
2014: 1st NABH (blood bank) accreditation for the hospital at Gurugram.
2016: 1st NABH accreditation for the hospital at Indore.
2018: 1st NABH accreditation for the hospital at Ranchi.
2020: 1st NABH accreditation for the Medanta Institutional Ethics Committee at the hospital at Gurugram.
2022: 1st NABH accreditation for the hospital at Lucknow.

Awards

2020: Hospital at Gurugram ranked as the best private hospital in India by Newsweek.
2021: Hospital at Gurugram featured in the top 200 global hospitals by Newsweek.
2021: Hospital at Gurugram ranked as the best private hospital in India by Newsweek.
2021: Hospital at Gurugram featured in the list of world’s best specialised hospitals for cardiology by Newsweek.
2021: Hospital at Gurugram awarded ‘Best Multi-Speciality Hospital – National’ at ‘The Economic Times Healthcare Awards, 2021’.
2021: Hospital at Gurugram ranked as the best multi-specialty private hospital in North India by The Week.
2021: Hospital at Gurugram was ranked first for emergency, neurology, gynaecology, and ranked second for cardiology, gastroenterology, nephrology, oncology and urology by The Times of India’s Critical Care Study 2021.
2022: Hospital at Gurguram featured in the list of world’s best specialised hospitals for cardiology and neurology by Newsweek.
2022: Hospital at Gurugram featured in the top 250 global hospitals by Newsweek.
2022: Hospital at Gurugram ranked as the best private hospital in India by Newsweek.
2022: Hospital at Gurugram ranked as the best multi-speciality private hospital in North India and the second best private hospital in India as per Best All India Multi Speciality Hospital Ranking 2022 by Outlook and NEB Research.

Major Events:

2009: Establishment and commencement of operations of Medanta – the Medicity Hospital at Gurugram.
2010: Leased premises for clinic at the Indira Gandhi International Airport, New Delhi.
2010: Leased premises for clinic at Defence Colony, New Delhi.
2013: Anant Investments (i.e., Investor Selling Shareholder) invested in Company.
2013: Leased premises for clinic at DLF Cybercity.
2014: Entered into a 27-year lease for hospital at Indore.
2015: Dunearn Investments (Mauritius) Pte Ltd invested in Company.
2015: Entered into a 15-year lease for hospital at Ranchi.
2015: GHPPL entered into a 33-year concession agreement with Governor of Bihar for the development, operation and maintenance of a proposed hospital on public-private partnership at Patna.
2016: Entered into a 90-year lease for a proposed hospital at Noida.
2019: Commencement of operations of new hospital at Lucknow by MHPL.
2020: Gurugram hospital outpatient department pharmacy taken in-house.
2020: Launch of outpatient department at hospital at Patna by GHPPL.
2021: Lucknow hospital outpatient department pharmacy taken in-house.
2021: Indore hospital outpatient department pharmacy taken in-house.
2021: Ranchi hospital outpatient department pharmacy taken in-house.
2021: Launch of outpatient department pharmacy at south Delhi clinic.
2022: Patna hospital’s inpatient department facility commenced operations.
2022: Launch of Patna hospital outpatient department pharmacy.
2022: Leased premises for clinic at Subhash Chowk.